KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) Operating Expenses (2018 - 2025)

Historic Operating Expenses for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$802.0 million.

  • BioNTech SE's Operating Expenses fell 696.46% to -$802.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 billion, marking a year-over-year increase of 160.9%. This contributed to the annual value of -$3.0 billion for FY2024, which is 2142.96% down from last year.
  • As of Q3 2025, BioNTech SE's Operating Expenses stood at -$802.0 million, which was down 696.46% from -$709.5 million recorded in Q2 2025.
  • BioNTech SE's 5-year Operating Expenses high stood at -$299.7 million for Q2 2021, and its period low was -$813.6 million during Q2 2024.
  • In the last 5 years, BioNTech SE's Operating Expenses had a median value of -$642.4 million in 2022 and averaged -$590.9 million.
  • In the last 5 years, BioNTech SE's Operating Expenses tumbled by 13181702298.41% in 2021 and then surged by 1279.23% in 2025.
  • Over the past 5 years, BioNTech SE's Operating Expenses (Quarter) stood at -$460.3 million in 2021, then tumbled by 39.56% to -$642.4 million in 2022, then fell by 17.58% to -$755.4 million in 2023, then decreased by 2.22% to -$772.2 million in 2024, then fell by 3.86% to -$802.0 million in 2025.
  • Its Operating Expenses was -$802.0 million in Q3 2025, compared to -$709.5 million in Q2 2025 and -$665.3 million in Q1 2025.